TMCnet News
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva BioPharma Corp. And Encourages Investors To Contact The Firm For Additional InformationThe securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synageva BioPharma Corp. ("Synageva" or the "Company") (Nasdaq: GEVA) relating to the proposed buyout of the Company by Alexion Pharmaceuticals, Inc. Under the terms of the transaction, Synageva shareholders are anticipated to receive $115 in cash and 0.6581 shares of Alexion for each share of Synageva they own. Based on Alexion's closing price on May 5, 2015, Synageva shareholders would have received compensation valued at approximately $225.92 per share. The transaction may undervalue Synageva and may result in a substantial loss for many shareholders. For example, according to Yaoo! Finance, at least one Wall Street analyst has issued a price target for Synageva stock at $230.00 per share. The firm's investigation seeks to determine, among other things, whether the Company's Board of Directors failed to satisfy their duties to shareholders, including whether the Board adequately pursued alternatives to the acquisition and whether the Board obtained the best price possible for the Company's shares of common stock. If you currently own common stock of Synageva and believe that the proposed buyout price is too low, or you would like to learn more about the investigation being conducted by Brower Piven, please visit our website at http://www.browerpiven.com/currentinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.
|
